Last year also was a big one for Ossenkoppele. In May, he published two articles in JAMA Neurology on his BrightFocus-funded research. Both studies received international attention because they help confirm that Aβ peptide levels start to build up and aggregate long before Alzheimer’s symptoms develop, and are predictive of disease. Read the story and a Q/A with Ossenkoppele on the BrightFocus website: “Big Data Confirm Amyloid’s Role in Early Alzheimer’s.”
The information provided in this section is a public service of BrightFocus Foundation, and should not in any way substitute for the advice of a qualified healthcare professional, and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.
Some of the content in this section is adapted from other sources, which are clearly identified within each individual item of information.